Net Clinical Benefit of Edoxaban Versus Apixaban in Patients With Atrial Fibrillation and Coronary Artery Disease

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 3000 participants.

Also called NCT07753200

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 3,000 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07753200
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07753200. Randomized; single masking; primary purpose treatment. Start 2026-07-20 (actual); primary completion 2031-06-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Net Clinical Benefit of Edoxaban Versus Apixaban in Patients With Atrial Fibrillation and Coronary Artery Disease
Acronym
SMARTDECISION3
Condition
Atrial Fibrillation (AF)
Condition
Coronary Arterial Disease (CAD (coronary artery disease))
Intervention (Drug)
Edoxaban
Intervention (Drug)
Apixaban
Lead sponsor
Samsung Medical Center (class: other)

Record details

Record id
cardio:ct-nct07753200
Content hash
cf4228458b32290da1157daeedcc253d86ca64162ddcfd9978a4864dc20977b5